Commentary articles by EAS
EAS contributes to the discussion of new developments in the field of atherosclerosis and related disease with scientific commentary articles.
- EAS issues ‘call-to-action’ statement on women, lipids, and atherosclerotic cardiovascular disease
- Update to consensus statement on homozygous familial hypercholesterolaemia
- New consensus statement on lipoprotein(a)
- Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: levelling up access to treatment urgently needed
- Novel insights into lipoprotein(a): News from Atherosclerosis
- Global Familial Hypercholesterolemia Studies Collaboration (FHSC) highlights the challenges of care
- European Atherosclerosis Society Consensus Panel: New Statement on Triglyceride-Rich Lipoproteins and their Remnants
- Lipid Clinics Network targets suboptimal guideline implementation
- EAS Task Force gives practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients
- Latest European Atherosclerosis Society statement reaffirms commitment to the UN Sustainable Development Goals 2030 Agenda
- SAMSON, SAMS and nocebo effects
- Should we treat high LDL cholesterol in ´health´ elderly individuals?
- DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe.
- Residual inflammatory risk: lessons from trials for the future
- HDL markers in cardiovascular risk prediction: ethnicity matters
- Familial hypercholesterolemia: an urgent public health priority
- Homozygous familial hypercholesterolaemia: new hope for getting patients to goal
- Commentary discussing new evidence for early intervention to optimise population health, together with novel approaches that may offer solutions to the issue of poor adherence
- Commentary on Quantifying atherogenic lipoproteins – pragmatic guidance from the EAS/EFLM Joint Consensus Initiative
- Commentary on Rare Dyslipidaemia paper
- First insights from the EAS Familial Hypercholesterolaemia Collaboration Registry: FH is still underdiagnosed and undertreated
- New ESC/EAS guidelines for dyslipidaemia management published. What’s new?
- Highlights from the EAS2019 Congress in Maastricht, May 26-29, 2019
- Commentary on Novel therapeutics specific to lipoprotein(a) Lp(a)
- Commentary on Triglycerides and cardiovascular risk: apolipoprotein B holds the key
- A look back at 2018: What made the news?
- Commentary on Lipid guidelines in the USA and Europe: A meeting of the minds?
- Cholesterol and inflammatory risk: Insights from secondary and primary prevention
- Optimal cardiovascular health: also good for the brain
- New Joint Consensus Initiative on Quantifying Atherogenic Lipoproteins
- Commentary on Highlights of EAS Congress Lisbon
- EAS Consensus panel answers the questions on statin safety
- At the end of the ODYSSEY…what now for PCSK9 inhibition in practice?
- Commentary on the highs and lows of cardiovascular disease prevention
- Commentary on Peripheral arterial disease (PAD)
- Update on SAMS: Statin-Associated Muscle Symptoms
- ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors
- ESC/EAS Task Force provides practical guidance for PCSK9 inhibitors: who to target, LDL-thresholds, future insights
- 2016 Joint ESC/EAS Dyslipidaemia Guidelines published
- EAS 2016 Innsbruck Highlights
- Not at LDL cholesterol goal? Consider statin responsiveness
- Looking back at 2015 – what made the news
- Position paper on Paediatric FH from the EAS Consensus panel
- EAS 2015 Glasgow Highlights
- Position paper on SAMS from the EAS Consensus panel
- Lifestyle for CVD prevention: the priority is sustaining change
- EAS Consensus Panel Statement on Homozygous FH
- EAS Consensus Panel paper: Simplifying the definition of hypertriglyceridaemia
- Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods
- Improving the care of high-risk patients: The potential of PCSK9
- EAS Consensus Statement on FH: Improving the care of FH patients
- Gut microbiota: an environmental risk factor for cardiovascular disease
- HDL function and cardiovascular risk
- Triglyceride-rich lipoproteins and HDL